Clinical TrialID 4974
Uridine Adolescent Bipolar Depression Randomized Controlled Trial
NCT01805440
Bipolar Disorder|Bipolar Depression|Manic Depression
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final clinical_trial record.
- Clinical Trial Id
- 4974
- Evidence Id
- 4974
- Core Evidence Id
- 4974
- Source Clinical Trial Id
- 4954
- Herb2 Clinical Trial Id
- HBCT004954
- Nct Id
- NCT01805440
- Title
- Uridine Adolescent Bipolar Depression Randomized Controlled Trial
- Status
- Completed
- Phase
- Study Result
- Yes
- Study Condition
- Bipolar Disorder|Bipolar Depression|Manic Depression
- Study Type
- Interventional
- Study Design
- Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER
- Intervention
- DRUG: Uridine|DRUG: Placebo
- Intervention Allocation
- Randomized
- Intervention Model
- Parallel
- Intervention Mask
- Quadruple
- Intervention Purpose
- Other
- Gender
- All
- Age
- Child, Adult
- Enrollment
- 62
- Outcome Measure
- Change in GLX (Glutamate + Glutamine) to Creatine (Cr) Ratio in the Anterior Cingulate Cortex of the Brain, as Measured With Proton-1 Magnetic Resonance Spectroscopy (1H-MRS)., Magnetic Resonance Spectroscopy is a safe, non-invasive method for measuring brain chemicals thought to be involved in mood disorders, such as GLX (glutamate + glutamine). Previous research indicates that adolescents with bipolar depression have elevated Glx concentrations, compared with controls. The measurement of Glx with 1H-MRS has the potential to identify translational biomarkers of juvenile BD pathophysiology and treatment response., Baseline and 6 weeks|Change in Children's Depression Rating Scale-Revised (CDRS-R) Score., The CDRS-R is a brief rating scale based on a semi-structured interview with the participant (and/or their parent or guardian). The scale can be administered and scored in under 30 minutes. The CDRS-R gives you a single summary score -- with an interpretation of, and clinical recommendations for, six different score ranges. Total possible scores range from 17 to 113, with higher scores indicating more depressive symptoms reported by the participant (and/or their parent or guardian)., 6 weeks
- Sponsor Collaborator
- University of Utah|The Depressive and Bipolar Disorder Alternative Treatment Foundation
- Funded By
- OTHER
- Location
- University of Utah, Salt Lake City, Utah, 84108, United States
- Other Id
- University of Utah
- Start Date
- 2013-08
- Primary Completion Date
- 2015-12
- Completion Date
- 2015-12
- First Posted
- 2013-03-06
- Results First Posted
- 2018-03-12
- Last Update Posted
- 2018-03-12
- Study Document
- Study Url
- https://clinicaltrials.gov/study/NCT01805440
- Title Cn
- Title En
- Uridine Adolescent Bipolar Depression Randomized Controlled Trial
- Bilingual Status
- semi_complete